Feature | March 24, 2015

Patients 80 Years and Older Would Benefit from Aggressive Treatment

Study suggests older patients may be denied invasive treatments unnecessarily

March 24, 2015 — Patients over age 80 with acute coronary syndromes would likely benefit from more invasive tests and therapies that may otherwise be denied them due to their age, according to research presented at the American College of Cardiology (ACC) 2015 annual meeting.
 
The study focused on treatment approaches for older patients with non ST-elevation myocardial infarction (NSTEMI — a type of heart attack that is milder in the acute phase, but has a poor prognosis after six months or more) or the closely related condition unstable angina. Both conditions are caused by the buildup of plaque in the heart’s arteries.
 
In the study, patients 80 years and older who received invasive procedures that are typically offered to younger patients to evaluate and correct narrowed arteries had a 47 percent reduction in the study’s primary endpoint, a combined measure of subsequent heart attacks, urgent revascularization procedures, stroke and death, as compared to similar patients who were treated using a more conservative approach.
 
“Because people over 80 are underrepresented in clinical trials, they are less likely to receive treatment according to guidelines,” said Nicolai Tegn, M.D., a cardiologist at Rikshospitalet Oslo University Hospital in Norway and the study’s lead author. “Our study, which directly targets the over-80 population, is the first to demonstrate that a more invasive strategy results in better outcomes in these patients. I believe our study provides a sufficient basis to recommend an invasive approach.”
 
The study included 458 patients who were treated for NSTEMI or unstable angina at 16 health centers in Norway. Patients were randomly assigned to receive one of two treatment approaches. Half received a conservative approach, which included medications as needed but no invasive interventions. The other half underwent coronary angiography, a test in which a catheter is threaded into the arteries of the heart to release a dye that makes the extent of plaque buildup visible in an X-ray. Based on the results of this test, doctors referred patients for balloon angioplasty and/or stenting in which plaque blocking the arteries is pushed aside, heart bypass surgery in which narrowed coronary arteries are replaced by arteries grafted from elsewhere in the body, or non-invasive treatments, such as drugs.
 
Of the 225 patients receiving coronary angiography, 48 percent were subsequently treated with angioplasty or stenting and 3 percent were treated with bypass surgery. In a median follow-up time of 18 months, the group receiving coronary angiography showed a 47 percent reduction in the study’s primary endpoint — a composite of heart attack, urgent revascularization procedures, stroke and death. The study did not show significant differences in the secondary endpoint (death from any cause) or in the risk of bleeding complications.
 
According to U.S. life expectancy statistics, a person who reaches age 80 can expect to live an average of 8.2 years (in men) and 9.7 years (in women). 
 
“The ‘80-plus’ population is an extremely heterogeneous group, ranging from healthy individuals to people with severe illness,” Tegn said. “The fact that many 80- year-olds have nearly a decade of life ahead of them makes these results particularly noteworthy.” 
 
Acute coronary syndromes become more common with age. It is estimated that as many as four out of five Americans over age 80 have at least one of a variety of conditions related to the buildup of plaque in the heart’s arteries. NSTEMI and unstable angina are often managed with a combination of medications, lifestyle changes and dietary changes in older people. Coronary angiography testing, stenting and bypass surgery are typically offered less often for the elderly than for younger patients, though practices vary depending on physician preference and clinic capabilities. 
 
The researchers will continue to track patients’ outcomes over the coming years.
 
For more information: acc.org
 

Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now